Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2006 3
2007 1
2008 3
2009 6
2010 5
2011 7
2012 14
2013 13
2014 8
2015 5
2016 5
2017 7
2018 5
2019 6
2020 10
2021 11
2022 9
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: toh hc. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Organoids as an Enabler of Precision Immuno-Oncology.
Zhao J, Fong A, Seow SV, Toh HC. Zhao J, et al. Among authors: toh hc. Cells. 2023 Apr 14;12(8):1165. doi: 10.3390/cells12081165. Cells. 2023. PMID: 37190074 Free PMC article. Review.
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.
Kaya NA, Tai D, Lim X, Lim JQ, Lau MC, Goh D, Phua CZJ, Wee FYT, Joseph CR, Lim JCT, Neo ZW, Ye J, Cheung L, Lee J, Loke KSH, Gogna A, Yao F, Lee MY, Shuen TWH, Toh HC, Hilmer A, Chan YS, Lim TK, Tam WL, Choo SP, Yeong J, Zhai W. Kaya NA, et al. Among authors: toh hc. J Immunother Cancer. 2023 Aug;11(8):e007106. doi: 10.1136/jitc-2023-007106. J Immunother Cancer. 2023. PMID: 37586766 Free PMC article.
Tailoring precision immunotherapy: coming to a clinic soon?
Han S, Shuen WH, Wang WW, Nazim E, Toh HC. Han S, et al. Among authors: toh hc. ESMO Open. 2020;5 Suppl 1(Suppl 1):e000631. doi: 10.1136/esmoopen-2019-000631. Epub 2020 Sep 30. ESMO Open. 2020. PMID: 33558033 Free PMC article. Review.
Cancer immunotherapy-the end of the beginning.
Toh HC. Toh HC. Chin Clin Oncol. 2018 Apr;7(2):12. doi: 10.21037/cco.2018.04.03. Chin Clin Oncol. 2018. PMID: 29764157 Free article. No abstract available.
Immunotherapy for nasopharyngeal cancer-a review.
Jain A, Chia WK, Toh HC. Jain A, et al. Among authors: toh hc. Chin Clin Oncol. 2016 Apr;5(2):22. doi: 10.21037/cco.2016.03.08. Chin Clin Oncol. 2016. PMID: 27121882 Free article. Review.
119 results